3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Allergies -

New vaccine reduces the risk of shingles

AllergiesMay 29, 06

A new vaccine which reduces the risk of shingles (herpes zoster) for use in people 60 years of age and older has won approval from the U.S. Food and Drug Administration.

The vaccine, Zostavax, is designed to treat shingles which is caused by the reactivation of the virus that causes chickenpox and is a painful disease characterized by a blistering rash.

The varicella-zoster virus, the same virus that causes chickenpox, the varicella-zoster virus lies dormant following an attack of chickenpox, in certain nerve tissue and as people age, the virus sometimes reappears in the form of shingles.

Shingles is thought to affect 2 in every 10 people in their lifetime and manifests as clusters of blisters, which develop on one side of the body and can cause severe pain that may last for weeks, months or years after the virus reappears.

Jesse L. Goodman, MD, MPH, Director of FDA’s Center for Biologics Evaluation and Research, says the vaccine will give health care providers an important tool that can help prevent an illness that affects many older Americans and often results in significant chronic pain.

Drug manufacturer Merck says Zostavax is a live virus vaccine which boosts immunity against varicella-zoster and involves a single injection in the upper arm.

Zostavax was trialed in approximately 38,000 individuals throughout the United States who were 60 years of age and older.

In the trial half received Zostavax and half received a placebo and in a three year follow up it was found that in individuals ages 60 - 69 it reduced the occurrence of the disease by 64%.

In those who developed the disease despite the vaccine the duration of pain following the onset of shingles was slightly reduced.

The most common side effects experienced in people who received Zostavax were redness, pain and tenderness, swelling at the site of injection, itching and headache.

Print Version
comments powered by Disqus

  Cell-associated HIV mucosal transmission: The neglected pathway
  Study ties breathing problems, asthma to bone loss
  Slowing the allergic march
  Special infant formula may not prevent allergies
  Protein associated with allergic response causes airway changes in asthma patients
  Features of the metabolic syndrome common in persons with psoriasis
  Landmark Study Shows Suboptimal Asthma Care
  Asthma and Eczema Sufferers Have a Lower Risk of Developing a Cancer
  Does breastfeeding protect against asthma?
  Sleep apnea as common as asthma in German kids
  Rates of food sensitivity vary by country
  Association Discovered Between Eczema in Early Childhood and Psychological Problems


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site